In the United Kingdom the conventional treatment of growth hormone deficiency has been 4 IU pituitary human growth hormone (hGH) given intramuscularly three times a week. ' In an attempt to reproduce the normal physiological pattern of secretion of growth hormone, and thus achieve a greater growth response, the same total weekly dose has been given in daily subcutaneous injections.24 Studies in animals, in which the hormone was given intravenously, indicated that frequent doses are more effective than occasional ones. There are no data about pulsatile administration of hGH subcutaneously either in animals or in man; we therefore studied the effect of pulsatile administration on the rate of growth in a small group of children deficient in growth hormone.
Patients and methods
Four prepubertal children deficient in growth hormone (one boy and three girls with a mean age of 7-6 years, range 6-1-11-4 years) were studied. Three had already received the standard regimen (4 IU intramuscularly) and one was a new patient. The Table summarises Auxological data were collected at three monthly intervals by standard techniques. 6 The rate of growth is reported as raw data (centimetres per year) and the standard deviation score, defined as (X-X)/ S, where X is the rate of growth, X the mean rate of growth, and S the standard deviation for age and sex. 
Results
The Table summarises the results. When given the conventional regimen the new patient showed 'catch up' growth, which was maintained during both subcutaneous regimens. The rate of growth in the three children who had previously been treated was maintained or improved, although during the 0-6 IU regimen in case 2 the rate of growth fell because of non-compliance.
The rate of growth and standard deviation score of each child fell dramatically-after treatment stopped, the score falling from the mean pretreatment value of -2-1 (confidence interval -1-8 to -2-9) to -3-8 (-2.5 to 5-7) after treatment.
The growth hormone profiles from one patient are shown in the Figure and compared with the profile of a 6 year old boy growing at a rate yielding a standard deviation score of -0-6. Actual time is not shown as the injection times were not synchronous, spanning 2000-2100. The peak concentrations of growth hormone and areas under the curves were greatest during the highest dose regimen, but the mean time to the peak concentration was similar after 4 IU hGHI given intramuscularly, 2 IU hGH given subcutaneously, and the first pulse of 0-6 IU given subcutaneously (3-6, 3-9, and 2-8 hours, respectively); similar times were seen after the subsequent pulses. Peaks of growth hormone concentration were seen during the three dose regimen in all cases. The peak concentration and area under the curve were less than in the two other regimens, but the profile resembles the normal secretory pattern of growth hormone more closely than the profiles seen during the other regimens.
Discussion
In the United Kingdom a Medical Research Council working party concluded that an acceptable costbenefit ratio in the treatment of children deficient in growth hormone was achieved when a total weekly dose of 12 IU hGH was given intramuscularly in three equal doses. Albertsson-Wikland et al and Kastrup et al reported improved growth when hGH was given daily but in the same weekly dose to children previously established on the conventional regimen.2 3 More frequent injections in animals have produced a greater growth response. In this small study we compared the effects on growth and serum growth hormone concentrations during treatment with 4 IU hGH intramuscularly three nights a week, 2 IU hGH subcutaneously six nights a week, and 0-6 IU hGH subcutaneously six nights a week. We showed similar growth responses in all treatment groups despite greater serum concentrations of growth hormone during the two high dose regimens compared with the multiple pulse regimen. A longer study with larger numbers of patients to confirm or refute our results was not possible because hGlI was withdrawn from the market.
We were unable to show any resemblance between the growth hormone profile after 2 IU hGH and the normal secretory profile, as reported by Christiansen et al,4 The multiple pulse regimen came closer to replicating the normal profile in childhood. To mimic normality higher doses of growth hormone are required, and it would probably have to be given intravenously as in the animal experiments.'
The growth rates fell noticeably after treatment. A similar phenomenon was observed in a matched group (age, sex, and pubertal development) of 15 children deficient in growth hormone whose pretreatment rate of growth standard deviation score of -2-1 (SD 1.0) fell to -3-2 (SD 1.5) during the period after growth hormone was withdrawn from the market (p<()-01) (C G D Brook et al. Paper presented at meeting of European Society of Paediatric Endocrinology, Zurich, 1986). Tanner et al described 'regulatory' deceleration after withdrawal of treatment with hGH. with the effect waning by six months.7 We confirmed these findings Single dose and pulsatile treatment with human growth hormone in growth hormone deficiency 851 but found that the phenomenon was still present nine to 12 months after the end of treatment.
The optimal treatment regimen has yet to be established, but this may now be possible as synthetic growth hormone becomes more widely available.
SUMMARY Clinical features cannot differentiate rotavirus gastroenteritis from other types of diarrhoea. Sixty eight stool specimens were examined by nurses on an infant gastroenteritis ward. Of these, 69% were correctly classified by smell alone. The results are significant (p=0.009) and support the suggestion that rotavirus stools have a characteristic smell.
The appearance and smell of stools have always interested physicians,' and the smell of the stool has provided an important clue in establishing the original link between enteropathogenic Escherichia coli and neonatal gastroenteritis.2 The present study was undertaken because it was noticed that the nurses on a paediatric infectious disease ward usually diagnosed rotavirus gastroenteritis correctly before the results of culture were available. They considered the appearance and smell of the stools to be of diagnostic value. Our aim was to test the hypotheses that rotavirus gastroenteritis could be diagnosed by either the smell of the stool alone, or a combination of smell and appearance.
Patients and methods
Overnight stools were collected from 23 babies with diarrhoea, aged 0-18 months (mean 4.8 months), and coded by night staff. Table 1 shows the causes of the diarrhoea. The stools were randomised and examined by day staff at 9.00 am the next morning.
Each stool was examined in two ways. The first way by smell alone, the specimen pot being wrapped in a paper towel, and the nurse keeping her eyes closed. She was asked to classify it as rotavirus or not rotavirus; 'don't know' was not allowed. For the second examination the paper towel was removed and she was asked to inspect the stool and given the opportunity to change her opinion. Seven nurses made 68 examinations of 33 stool specimens over three months.
The ages of the children, the feeds given, and the ages of the stools were comparable. 
